TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28235116
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy plus standard care
Study: 25612493
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m²)
Study: 19359536
Drug: Early invasive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invasive treatment strategy (EIS)
Study: 19359536
Drug: Selective invasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective invasive treatment strategy (SIS)
Study: 15591013
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 and 4 grams per day)
Study: 6769159
Drug: Ketotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (1 mg twice daily)
Study: 2874780
Drug: Ketazolam once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketazolam once daily
Study: 2874780
Drug: Divided doses
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided doses of ketazolam (from earlier study)
Study: 27919356
Drug: niacin monotherapy
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin monotherapy (N = 118)
Study: 27919356
Drug: ezetimibe/simvastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin monotherapy (n = 155)
Study: 27919356
Drug: ezetimibe/simvastatin (10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin (10/20 mg) + niacin (to 2 g) (N = 279)
Study: 24172024
Drug: Classroom-based cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classroom-based cognitive-behavioural therapy (CBT)
Study: 15800981
Drug: LAM monotherapy
Normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LAM monotherapy (group A)
Study: 15800981
Drug: Initial interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial interferon plus LAM treatment followed by LAM monotherapy (group B)
Study: 12356387
Drug: Cerivastatin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 400 microg plus regular margarine 25 g
Study: 12356387
Drug: Cerivastatin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 400 microg plus sterol‐ester margarine 25 g
Study: 12356387
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus sterol‐ester margarine 25 g (2 g of plant sterol)
Study: 12356387
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus regular margarine 25 g
Study: 8567330
Drug: HFX RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX RT with 1.2 Gy twice daily, total dose of 64.8 Gy in 27 treatment days, shorter interfraction interval (4.5-5 h)
Study: 8567330
Drug: HFX RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX RT with concurrent chemotherapy (carboplatin and etoposide) every week, shorter interfraction interval (4.5-5 h)
Study: 8567330
Drug: HFX RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX RT with concurrent chemotherapy (carboplatin and etoposide) every other week, shorter interfraction interval (4.5-5 h)
Study: 8567330
Drug: HFX RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX RT with 1.2 Gy twice daily, total dose of 64.8 Gy in 27 treatment days, longer interfraction interval (5.5-6 h)
Study: 8567330
Drug: HFX RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX RT with concurrent chemotherapy (carboplatin and etoposide) every week, longer interfraction interval (5.5-6 h)
Study: 8567330
Drug: HFX RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX RT with concurrent chemotherapy (carboplatin and etoposide) every other week, longer interfraction interval (5.5-6 h)
Study: 25339518
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg twice daily during the open-label maintenance (OLM) study
Study: 30283499
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg twice daily
Study: 18073548
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg propofol at the end of surgery
Study: 15855580
Drug: Pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 45 mg for 3 months
Study: 7604145
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg BAHS before sleep for 6 months
Study: 2356213
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg/70 kg) at 6 hours postmorphine
Study: 2356213
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg/70 kg) at 24 hours postmorphine
Study: 2356213
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg/70 kg) at 6 and 24 hours postmorphine
Study: 2356213
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg/70 kg) at 24 hours postmorphine preceded by naloxone at 6 hours
Study: 7094642
Drug: Chlorpheniramine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine (8 mg)
Study: 31151425
Drug: Nutritional counseling,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional counseling, nutritional supplements (rich in branched-chain amino acids), and a home-based exercise program (low-intensity daily muscle training and lifestyle education).
Study: 31151425
Drug: Nutritional counseling,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional counseling, nutritional supplements, and exercise program (as above).
Study: 28556061
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ASA intravenously
Study: 28556061
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg enteric-coated ASA bid
Study: 28556061
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg chewable ASA
Study: 26033265
Drug: Adjuvant intensity-modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant intensity-modulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin (TP)
Study: 23878192
Drug: Xylazine (1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylazine (1.1 mg/kg)
Study: 19623203
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (3.5 g/day, 1.5 g/day total n-3 PUFA)
Study: 17444382
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment combined with cycloidal vibration therapy (Vibro‐Pulse), 30 minutes per treatment, three times per day
Study: 17444382
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (intravenous or oral antibiotic therapy) and bed rest
Study: 11718589
Drug: Intranasal corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal corticosteroid (fluticasone propionate)
Study: 11718589
Drug: Oral antihistamine
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antihistamine (loratadine)
Study: 3069539
Drug: Buprenorphine 0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.30 mg
Study: 31982581
Drug: 2 mg,
Normalized name: Liletta 52 MG, 8 Year Intrauterine System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg, 5 mg, or 10 mg PedPRM nightly up to 104 weeks
Study: 31982581
Drug: PedPRM (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PedPRM (2, 5, or 10 mg nightly)
Study: 26275761
Drug: Parent-coached exposure
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-coached exposure therapy
Study: 23114849
Drug: LGG plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGG plus smectite (3 g)
Study: 21420788
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetaminophen and tropisetron
Study: 18822830
Drug: Nonstimulant medications
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonstimulant medications
Study: 16642613
Drug: Fluoxetine (medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (medication group)
Study: 23557025
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment only (Control)
Study: 29991122
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation together with 10 sessions of WBMF therapy
Study: 22904565
Drug: AMI cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMI cell infusion (n = 57)
Study: 22904565
Drug: OMI cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMI cell infusion (n = 22)
Study: 22904565
Drug: Cell infusion
Normalized name: irrigation set MISCELL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell infusion group (n = 79)
Study: 15928071
Drug: Paclitaxel at
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel at 175 mg/m2 plus Carboplatin at 7 AUC (Arm A)
Study: 15928071
Drug: Paclitaxel at
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel at 175 mg/m2 plus alternating Carboplatin at 7 AUC and Cisplatin at 75 mg/m2 (Arm B)
Study: 8826549
Drug: 0.2 mL
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mL NaCl 0.9%
Study: 8826549
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL NaCl 0.9%
Study: 8826549
Drug: 1.0 mL
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mL NaCl 0.9%
Study: 8826549
Drug: 1.5 mL
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL NaCl 0.9%
Study: 1598734
Drug: Thiphenamil 400
Normalized name: thiphenamil 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiphenamil 400 mg q.i.d.
Study: 24769557
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy using the Amadeo Robotic System
Study: 24769557
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy executed by a trained physiotherapist
Study: 17432677
Drug: Modified Daotan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Daotan Decoction (DD) + risperidone 3.16 +/- 0.73 mg/d
Study: 17432677
Drug: Risperidone 5.11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 5.11 +/- 1.27 mg/d
Study: 9066933
Drug: Ticlopidine 250
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 250 mg
Study: 8378946
Drug: Warfarin (INR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (INR 2.0 to 4.5)
Study: 2947151
Drug: Trimetazidine 60
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 60 mg
Study: 29180306
Drug: Control (nonpharmacologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (nonpharmacologic treatment)
Study: 10648489
Drug: Tedisamil 50
Normalized name: tedisamil
DrugBank: Tedisamil (DB06200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tedisamil 50 mg twice daily
Study: 10648489
Drug: Tedisamil 100
Normalized name: tedisamil
DrugBank: Tedisamil (DB06200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tedisamil 100 mg twice daily
Study: 10648489
Drug: Tedisamil 150
Normalized name: tedisamil
DrugBank: Tedisamil (DB06200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tedisamil 150 mg twice daily
Study: 1281648
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment in receptor-defined subgroups
Study: 30993423
Drug: High cumulative
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cumulative dose of DMF exposure
Study: 26471495
Drug: GDFT (Goal
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDFT (Goal Directed Fluid Therapy)
Study: 26471495
Drug: CONTROL (no-protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: CONTROL (no-protocol treatment)
Study: 19552020
Drug: Multisubstrate nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisubstrate nutritional cocktail (0.3 g/kg protein weight, 7.5 g fibers per day, 10 kcal/kg body weight) in addition to conventional treatment.
Study: 19552020
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (lactulose, beta-blocker, spironolactone based on 1.2 g/kg protein weight and 30 kcal/kg body weight per day).
Study: 18572750
Drug: saquinavir/ritonavir 1,600/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: saquinavir/ritonavir 1,600/100 mg per day plus two NRTIs
Study: 12092000
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue (Quixil) - 0.3 ml sprayed to each bleeding nostril
Study: 10363623
Drug: 0.3% netilmicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% netilmicin ophthalmic solution
Study: 1984711
Drug: Dextroamphetamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (0.25 mg/kg)
Study: 1664978
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (daily injection)
Study: 1664978
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (in patients with fractures)
Study: 31229205
Drug: Classical massage
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical massage (CMG) before each paclitaxel infusion
Study: 23524688
Drug: Hydrogel with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel with BMP-2 (250 µg/mL)
Study: 17869307
Drug: Tookad vascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tookad vascular targeted photodynamic therapy (0.1 to 2 mg/kg) with a fixed light dose of 100 J/cm
Study: 17869307
Drug: Tookad vascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tookad vascular targeted photodynamic therapy (2 mg/kg) with escalated light doses of 230 and 360 J/cm
Study: 17869307
Drug: Tookad vascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tookad vascular targeted photodynamic therapy
Study: 15650343
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg plus statin (lovastatin, pravastatin, simvastatin, atorvastatin)
Study: 15650343
Drug: Statin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin monotherapy (lovastatin or pravastatin 10, 20, or 40 mg; simvastatin or atorvastatin 10, 20, 40, or 80 mg)
Study: 11589675
Drug: DHEA 50
Normalized name: Natrol Mood & Stress DHEA 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 50 mg per day for 4 months (n = 14)
Study: 3126350
Drug: recombinant tissue‐type
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant tissue‐type plasminogen activator (rt‐PA) 80 mg
Study: 3126350
Drug: old rt‐PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: old rt‐PA 80 mg
Study: 3126350
Drug: new rt‐PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: new rt‐PA 80 mg
Study: 3126350
Drug: new rt‐PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: new rt‐PA 100 mg
Study: 3126350
Drug: new rt‐PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: new rt‐PA 150 mg
Study: 3126350
Drug: new rt‐PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: new rt‐PA (various doses)
Study: 15737106
Drug: conventional antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional antipsychotic agents
Study: 10599054
Drug: Cholinesterase inhibitor
Normalized name: Acetylcholinesterase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitor metrifonate (MTF) treatment for 6 months
Study: 10599054
Drug: Cholinesterase inhibitor
Normalized name: Acetylcholinesterase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitor metrifonate (MTF) treatment for 2 years or more
Study: 10599054
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (off MTF)
Study: 10599054
Drug: Cholinesterase inhibitor
Normalized name: Acetylcholinesterase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitor metrifonate (MTF) treatment
Study: 1773579
Drug: Nomogram for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomogram for dosing warfarin
Study: 1773579
Drug: Computer program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer program for dosing warfarin
Study: 7053286
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs prescribed to 63% of patients
Study: 7053286
Drug: More vigorous
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More vigorous treatments prescribed
Study: 7053286
Drug: Patient compliance
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient compliance with treatment
Study: 11834957
Drug: Surgical Treatment
Normalized name: SURGICAL AIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical Treatment (ST)
Study: 25533021
Drug: Combined individual
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined individual dietary counseling with individualized swallowing therapy
Study: 23972414
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for relatively active patients
Study: 23972414
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for passive patients
Study: 18761065
Drug: Riboflavin-5'-phosphate sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin-5'-phosphate sodium salt (RF5P) delivered via gastro-mucoadhesive delivery system based on ion-exchange fiber; specific dosage and duration not mentioned.
Study: 18761065
Drug: Modified dissolution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified dissolution system (flow through diffusion cell) used to study drug release; specific details not mentioned.
Study: 18761065
Drug: Analysis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analysis of urinary excretion of riboflavin in humans; specific details not mentioned.
Study: 16822237
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (4 g/day)
Study: 16822237
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil supplementation (4 g/day)
Study: 12814446
Drug: 08.00 h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 08.00 h dosing of 3 micro g oral vitamin D3
Study: 12814446
Drug: 20.00 h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20.00 h dosing of 3 micro g oral vitamin D3
Study: 8241702
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (100 mg per day) given orally for 14 days before and 30 days after surgery
Study: 2859412
Drug: HB immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB immunoglobulin and 2 doses of HB vaccine 2 months apart
Study: 2859412
Drug: HB immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB immunoglobulin and 3 doses of HB vaccine 1 month apart
Study: 2859412
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of vaccine 2 months apart
Study: 2859412
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of vaccine 1 month apart
Study: 3544689
Drug: 2-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose regimen
Study: 3544689
Drug: 3-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose regimen
Study: 26524984
Drug: Narrowband ultraviolet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrowband ultraviolet B (NB‐UVB) exposures, 2 standard erythema doses (SEDs) every second week from October 2013 to April 2014
Study: 22878869
Drug: Tropisetron (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (0.1 mg/kg; maximal dose, 5 mg)
Study: 22878869
Drug: Tropisetron (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (0.1 mg/kg; maximal dose, 5 mg) plus Penehyclidine (0.01 mg/kg; maximal dose, 1 mg)
Study: 22878869
Drug: Penehyclidine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penehyclidine (0.01 mg/kg; maximal dose, 1 mg)
Study: 15867284
Drug: Low-fat, high-fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat, high-fiber diet with 25 g/d soy protein (+ 90 mg/d isoflavones)
Study: 15867284
Drug: Low-fat, high-fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat, high-fiber diet with 25 g/d milk protein
Study: 11593526
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 to 50 mg bid for 12 weeks
Study: 3934964
Drug: Antihyperglycemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihyperglycemic therapy
Study: 3934964
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg per day of sorbinil
Study: 17715389
Drug: Nilotinib 400
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 400 mg orally twice daily
Study: 25911523
Drug: Remote therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote therapy from University lab
Study: 25911523
Drug: Remote therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote therapy from clinical site
Study: 22435769
Drug: Face to
Normalized name: NAIR FACE TOP CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face to face therapy
Study: 24407777
Drug: Fixed tapering
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed tapering dose regimen of lorazepam
Study: 15944868
Drug: Estrogen patch
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen patch for 36 hours